Advertisement

Breast Cancer Research and Treatment

, Volume 124, Issue 3, pp 677–688 | Cite as

Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma

  • Fangfang Liu
  • Lifang Cui
  • Yang Zhang
  • Ling Chen
  • Yahong Wang
  • Yu Fan
  • Ting Lei
  • Feng Gu
  • Ronggang Lang
  • Gordon A. Pringle
  • Xinmin Zhang
  • Zhinan ChenEmail author
  • Li FuEmail author
Preclinical study

Abstract

HAb18G is a recently identified hepatoma-associated antigen and its association with tumor growth, invasion, and angiogenesis has been studied in a variety of tumors. However, its role in the tumor progression of breast cancer has not been explored. HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC). While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01). Its expression in BC was correlated positively with C-erbB-2 expression and histologic grade (P < 0.001), and negatively with the expression of estrogen and progesterone receptors (P < 0.001). Significant differences of expression were also identified among the subgroups of BC examined: in decreasing order from invasive micropapillary carcinoma, ductal carcinoma, lobular carcinoma, papillary carcinoma, medullary carcinoma, to mucinous adenocarcinoma (P = 0.001), corresponding to their known clinical aggressiveness. In an expanded group of 186 BC patients with proper follow up, our previous findings were confirmed: HAb18G expression was significantly associated with local recurrence, distant metastasis and tumor mortality (P < 0.01). We also demonstrated that up-regulated tumor expression of HAb18G was a significant predictor of reduced disease progression-free survival rate and a shorter overall survival, independent of systemic therapies. In conclusion, this study suggests that HAb18G expression is associated with BC progression and prognosis. Further evaluation of this new marker in breast cancer is indicated.

Keywords

HAb18G Breast carcinoma Immunohistochemistry Tumor progression Prognosis 

Notes

Acknowledgments

Supported by grants from National “863” Program of China (2006AA02A249), National “973” Program of China (2009CB521700) and the Program for Changjiang Scholars and Innovative Research Team in University (IRT0743).

Supplementary material

10549_2010_790_MOESM1_ESM.pdf (62 kb)
Supplementary material 1 (PDF 62 kb)

References

  1. 1.
    Chen ZN, Liu YF (1990) Monoclonal antibody HAb18 to human hepatoma. Monoclon Antib 8:11Google Scholar
  2. 2.
    Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC (2001) The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 276(50):46870–46877CrossRefPubMedGoogle Scholar
  3. 3.
    Chen ZN, Shang P, Li Y, Qian AR, Zhu P, Xing JL, inventors (2002) NTD patent & trademark agency Ltd., Beijing office, assignee. HAb18G/CD147, its agonist and application. Chinese patent ZL01131735.3, 2001 Sep 28; PCT international patent WO02/094875, 27 May 2002Google Scholar
  4. 4.
    Huang Y, Jiang J, Dou K, Chen Z (2005) HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Eur J Cell Biol 84(1):59–73CrossRefPubMedGoogle Scholar
  5. 5.
    Li Y, Shang P, Qian AR, Wang L, Yang Y, Chen ZN (2003) Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol 9(10):2174–2177PubMedGoogle Scholar
  6. 6.
    Wang FQ, So J, Reierstad S, Fishman DA (2006) Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 118(4):879–888CrossRefPubMedGoogle Scholar
  7. 7.
    Jiang JL, Chan HC, Zhou Q, Yu MK, Yao XY, Lam SY, Zhu H, Ho LS, Leung KM, Chen ZN (2004) HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. Cell Mol Life Sci 61(16):2083–2091CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen Z (2006) CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 5(7):808–814CrossRefPubMedGoogle Scholar
  9. 9.
    Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, Chen GS, Li Q, Qian F, Tian R, Wen N, Chen ZN (2007) Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev 16(3):196–202CrossRefPubMedGoogle Scholar
  10. 10.
    Bao GQ, Li Y, Ma QJ, He XL, Xing JL, Yang XM, Chen ZN (2005) Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol Ther 4(12):1374–1380CrossRefPubMedGoogle Scholar
  11. 11.
    Chen ZN, Mi L, Xu J et al (2006) Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 65(2):435–444PubMedGoogle Scholar
  12. 12.
    Xu J, Shen ZY, Chen XG et al (2007) A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45(2):269–276CrossRefPubMedGoogle Scholar
  13. 13.
    Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, Tsuneyama K, Takano Y (2006) Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 95(10):1371–1378CrossRefPubMedGoogle Scholar
  14. 14.
    Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, Chen ZN (2008) CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 75(3–4):230–236CrossRefPubMedGoogle Scholar
  15. 15.
    Sienel W, Polzer B, Elshawi K, Lindner M, Morresi-Hauf A, Vay C, Eder F, Passlick B, Klein CA (2008) Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol 21(9):1130–1138CrossRefPubMedGoogle Scholar
  16. 16.
    Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119(8):1800–1810CrossRefPubMedGoogle Scholar
  17. 17.
    Li Y, Xu J, Chen L et al (2009) HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 54(6):677–687CrossRefPubMedGoogle Scholar
  18. 18.
    McShane LM et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072CrossRefPubMedGoogle Scholar
  19. 19.
    Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F, Fu L (2009) Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol 100(2):89–94CrossRefPubMedGoogle Scholar
  20. 20.
    Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145CrossRefPubMedGoogle Scholar
  21. 21.
    Guo H, Li R, Zucker S, Toole BP (2000) EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 60(4):888–891PubMedGoogle Scholar
  22. 22.
    Kanekura T, Chen X, Kanzaki T (2002) Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99(4):520–528CrossRefPubMedGoogle Scholar
  23. 23.
    Xu J, Xu HY, Zhang Q et al (2007) HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 5(6):605–614CrossRefPubMedGoogle Scholar
  24. 24.
    Tavassoli FA, Devilee P (2003) WHO classification of tumours. Pathology & genetics tumours of the breast and female genital organs. Lyon, IARC Press, pp 28–29Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Fangfang Liu
    • 1
  • Lifang Cui
    • 1
  • Yang Zhang
    • 2
  • Ling Chen
    • 1
  • Yahong Wang
    • 1
  • Yu Fan
    • 1
  • Ting Lei
    • 1
  • Feng Gu
    • 1
  • Ronggang Lang
    • 1
  • Gordon A. Pringle
    • 3
  • Xinmin Zhang
    • 3
  • Zhinan Chen
    • 2
    Email author
  • Li Fu
    • 1
    Email author
  1. 1.Department of Breast Cancer Pathology and Research Laboratory, State Key Laboratory of Breast Cancer ResearchCancer Hospital of Tianjin Medical UniversityTianjinChina
  2. 2.Cell Engineering Research Centre & Department of Cell Biology, State Key Laboratory of Cancer BiologyFourth Military Medical UniversityXi’anChina
  3. 3.Department of Pathology and Laboratory MedicineTemple University HospitalPhiladelphiaUSA

Personalised recommendations